<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00203177</url>
  </required_header>
  <id_info>
    <org_study_id>TVP - 1012/135 Double Blind</org_study_id>
    <nct_id>NCT00203177</nct_id>
  </id_info>
  <brief_title>Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.</brief_title>
  <official_title>A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5
      mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with
      Levodopa/Carbidopa therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>long-term safety and tolerability of rasagiline</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the long-term safety and tolerability of rasagiline in PD patients with motor fluctuations treated with chronic levodopa/carbidopa (LD/CD) or levodopa/benserazide (LD/BZD) therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>long- term clinical effect of rasagiline</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the long- term clinical effect of rasagiline on the course of the disease.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">254</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg rasagiline mesylate oral once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expermental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg rasagiline mesylate oral once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rasagiline mesylate</intervention_name>
    <description>0.5 rasagiline mesylate</description>
    <arm_group_label>Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rasagiline mesylate 1.0 mg</intervention_name>
    <description>1.0 mg rasagiline mesylate</description>
    <arm_group_label>Expermental 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have completed the Week 26 visit of TVP 1012/133 (Visit 06) in
             accordance with the protocol.

          -  Women must be postmenopausal, surgically sterile, or using adequate birth control
             methods. Women of childbearing potential must have a negative pregnancy test at
             Baseline/Month 0.

          -  Patients must be willing and able to give informed consent.

        Exclusion Criteria:

          -  Serious or severe, test drug-related (probable or definite) adverse reaction in study
             TVP 1012/133.

          -  Premature discontinuation from study TVP 1012/133 for any reason.

          -  A clinically significant or unstable medical or surgical condition which would
             preclude safe and complete study participation. Such conditions may include
             cardiovascular, pulmonary hepatic, renal, metabolic diseases or malignancies as
             determined by medical history, physical exam, skin evaluation, laboratory tests, chest
             x-ray, or ECG.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis Salzman, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Teva Neuroscience, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Margolin Brain Institute</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush - Presbyterian St. Luke's Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM-Hotel-Dieu</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2w1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 8, 2010</last_update_submitted>
  <last_update_submitted_qc>March 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Siyu Liu, MD, PhD, VP IR&amp;D, Head of Global Clinical Operations</name_title>
    <organization>Teva Branded Pharmaceutical Products IR&amp;D</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

